Novo Nordisk

In the last 4 hours

Hanmi seeks to gain on Wegovy with its own weight-loss drug Korea JoongAng Daily04:27

In the last 6 hours

Novo Nordisk Korea signs MOU with SNUBH to advance future medical technologies Korea Biomedical Review02:46

Yesterday

Novo Nordisk: Excellent Opportunity To Buy The Dip Seeking Alpha17:28 15-Jan-25

Lotte Bjerre Knudsen: The Scientist Who Drove GLP-1 Drugs For Obesity and Alzheimer's Ground Truths16:36 15-Jan-25

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss? 24/7 Wall St.14:09 15-Jan-25

The 5 most Ozempic states in America — and the 4 least Quartz10:04 15-Jan-25

Conn. City Hits PBMs And Pharma Cos. With Insulin Pricing Suit Law36003:26 15-Jan-25

In the last 7 days

Mass. AG Says Insulin Makers, Middlemen Colluded On Costs Law36018:35 14-Jan-25

Novo-Nordisk is Now Oversold (NVO) Nasdaq17:23 14-Jan-25

DarioHealth Expands GLP-1 Weight-Loss Solution, Unlocking New Revenue Streams in Rapidly… Business Wire (Press Release)17:14 14-Jan-25

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday The Motley Fool17:12 14-Jan-25

Ozempic Costs Could Rise in Trump's Quest for Greenland NewsMax16:12 14-Jan-25

Novo Nordisk excitement starts to build ahead of February results Proactive Investors (UK)11:02 14-Jan-25

Ozempic Maker Says Atlanta Clinic Misuses TM To Sell Meds Law36001:06 14-Jan-25

FTC decided not to block an acquisition that could impact supply and prices of important medicines. U.S. PIRG22:08 13-Jan-25

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock. Barchart15:46 13-Jan-25

Novo Nordisk A/S - share repurchase programme GlobeNewswire (Press Release)13:54 13-Jan-25

Trump Could Frankly Learn a Lot From Denmark The New Republic00:00 13-Jan-25

Houston-area health care providers see rising demand for diabetes, obesity drugs Community Impact Newspaper19:26 10-Jan-25

Companies roundup: Terry Smith, Alliance Pharma and Sainsbury’s Investors Chronicle12:29 10-Jan-25

Top 2 Best Places to Work in Bangladesh for 2024 Revealed MediaOutReach (Press Release)09:35 10-Jan-25

Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills? Invezz08:52 10-Jan-25

Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains Mint06:51 10-Jan-25

Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025? Barchart02:25 10-Jan-25

Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS Scrip Pharma Intelligence23:37 9-Jan-25

Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea Yahoo! US21:29 9-Jan-25

Ozempic Company Responds After Trump Tariff Threats on Denmark Miami Herald17:58 9-Jan-25

NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy Zacks14:35 9-Jan-25

Aspect Biosystems secures $115m to develop tissue therapeutics Pharmaceutical Technology11:55 9-Jan-25

London-based Ozempic rival launches with huge £333.5m Series A UKTN (UK Tech News)10:25 9-Jan-25

Novo Nordisk and Valo expand cardiometabolic drug partnership Pharmaceutical Technology10:23 9-Jan-25

Top 2 Best Places to Work in Indonesia for 2024 announced MediaOutReach (Press Release)09:33 9-Jan-25

UK Biotech Startup Takes Aim at Weight-Loss Leaders Novo, Lilly BNN Bloomberg07:34 9-Jan-25

Aspect Biosystems raises US$115 million, prepares to advance its health-tech innovations BC Business Magazine01:56 9-Jan-25

In the last month

AI Wants to be the Future of Drug Discovery Power Corridor23:56 8-Jan-25

100% Tariffs on Goods from Denmark – Doubling the Price of Ozempic? Econbrowser (Weblog)23:30 8-Jan-25

Aspect Biosystems raises US$115 million in Series B funding Voxel Matters19:59 8-Jan-25

Looking to Revolutionalize Advanced Therapy Manufacturing Genetic Engineering and Biotechnology News19:06 8-Jan-25

Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone' Yahoo! US18:08 8-Jan-25

Collaborative effort targets better nutrition for pregnant women and children News-Medical.Net18:00 8-Jan-25

Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs Yahoo! US15:55 8-Jan-25

Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk The Motley Fool15:34 8-Jan-25

Trump suggests Denmark tariff. How it could hit Novo Nordisk. Yahoo! UK & Ireland15:13 8-Jan-25

This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly The Motley Fool14:53 8-Jan-25

Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals Benzinga14:52 8-Jan-25

Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower Benzinga14:12 8-Jan-25

Novo Nordisk swells alliance with AI firm Valo Health pharmaphorum13:50 8-Jan-25

Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes FierceBiotech13:07 8-Jan-25

Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue… Business Wire (Press Release)13:04 8-Jan-25

11 blockbuster drugs to look out for in 2025 pharmaphorum12:08 8-Jan-25

Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases GlobeNewswire (Press Release)11:33 8-Jan-25

Metsera announces positive results in newest Phase IIa GLP-1RA Clinical Trials Arena09:48 8-Jan-25

Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment Pharmaceutical Technology23:51 7-Jan-25

Combating Obesity: Weight Loss by Pill The Globalist17:00 7-Jan-25

Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share… FierceBiotech15:47 7-Jan-25

Novo Nordisk partners with Variant Bio; Aviceda raises $207M in Series C ENDPOINTS15:43 7-Jan-25

Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns Benzinga13:47 7-Jan-25

Novo Nordisk Poised for Short-Term Gains, while Eli Lilly Promises Stronger Long-Term Growth TipRanks13:28 7-Jan-25

Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk to Discover Novel… PR Newswire (Press Release)12:10 7-Jan-25

Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential Seeking Alpha00:51 7-Jan-25

Why 2025 will be an inflection for Novo Nordisk, Eli Lilly's GLP-1s Yahoo! UK & Ireland18:01 6-Jan-25

Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug Benzinga13:26 6-Jan-25

Novo Nordisk asks FDA not to allow GLP-1 compounding pharmaphorum10:57 6-Jan-25

Wegovy maker Novo Nordisk’s fishy advertising practices exposed Marketing Beat10:16 6-Jan-25

Lilly Has The Upper Hand In Obesity In 2025 But Novo Has More Cards To Play Scrip Pharma Intelligence10:02 6-Jan-25

Is Novo Nordisk an Undervalued Stock to Buy Now? The Motley Fool09:32 6-Jan-25

A New Theory of Purposeful Enterprise CLS Blue Sky05:56 6-Jan-25

What's Going on With Novo Nordisk Stock? The Motley Fool10:25 5-Jan-25

Wegovy maker Novo Nordisk sponsored British pharmacies in pursuit of sales Yahoo! UK & Ireland19:09 4-Jan-25

Better Buy: Novo Nordisk vs. AstraZeneca The Motley Fool10:51 4-Jan-25

European Growth Segment Hit by Novo Nordisk Decline Morningstar16:38 3-Jan-25

From Davids to Goliaths: the GLP-1R gold rush Pharmaceutical Technology12:21 3-Jan-25

1st Private Co. Joins Insulin Price-Fixing MDL Law36000:35 3-Jan-25

Ozempic Caused Severe Pain And Hospitalization, Suit Says Law36023:44 2-Jan-25

Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst Clinical Trials Arena17:15 2-Jan-25

China Diabetes Device Market Forecast Report and Company Analysis 2024-2032 Featuring Roche,… Business Wire (Press Release)16:57 2-Jan-25

US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report Benzinga14:26 2-Jan-25

To see what European business could become, look to the Nordics The Economist14:13 2-Jan-25

Tirzepatide outpacing Wegovy in the obesity space Pharmaceutical Technology14:10 2-Jan-25

Should You Buy the Dip in Novo Nordisk Stock Right Now? The Motley Fool13:32 2-Jan-25

Why the Obesity Drug Revolution Is a Work in Progress BNN Bloomberg11:38 2-Jan-25

2025 is the Year of the Weight Loss Pill Power Corridor11:07 2-Jan-25

Novo Nordisk: Be Greedy When Others Are Fearful Seeking Alpha11:08 1-Jan-25

It’s getting harder to claim success with weight reduction drugs Mint09:36 1-Jan-25

Why are Nordic companies so successful? The Straits Times21:52 31-Dec-24

GLP-1 questions emerge for 2025 Yahoo! US21:50 31-Dec-24

Weight-loss drug investments: why 2025 could be a game-changer Invezz17:50 31-Dec-24

Historical Trends Warrant a Closer Look at Novo Nordisk (NVO) Call Options TipRanks22:20 30-Dec-24

Hunt for next obesity breakthrough sends biotech stock soaring European Pharmaceutical Manufacturer16:09 30-Dec-24

Stock Watch: Pfizer And Novo Nordisk Deliver Christmas Gifts Both Welcome And Unwanted Scrip Pharma Intelligence14:02 30-Dec-24

3 Stocks That Could Be Monster Winners in 2025 The Motley Fool11:52 29-Dec-24

Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry… The Motley Fool10:40 29-Dec-24

Is Eli Lilly Stock a Buy? The Motley Fool09:39 29-Dec-24

2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades The Motley Fool11:06 28-Dec-24

The bar for successful obesity drugs is rising The Guam Daily Post02:58 28-Dec-24

A new medicine for almost everything – is it too good to be true? ScienceNorway23:04 27-Dec-24

Lisa Jarvis: The bar for successful obesity drugs is rising The Fresno Bee09:19 27-Dec-24

Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over? Benzinga20:03 26-Dec-24

Elon Musk Prefers Eli Lilly’s (LLY) Mounjaro over Novo Nordisk’s Ozempic TipRanks17:52 26-Dec-24

Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear. The Motley Fool15:18 26-Dec-24

Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY Zacks13:38 26-Dec-24

Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy? The Motley Fool13:06 26-Dec-24

Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst Yahoo! UK & Ireland11:41 25-Dec-24

Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived Seeking Alpha00:19 25-Dec-24

What's next for GLP-1 weight-loss drugs in 2025? Yahoo! US19:47 24-Dec-24

Productivity Shocks to the Pharmaceutical Sector and the Danish Economy: Denmark International Monetary Fund (Press Release)19:41 24-Dec-24

The Next Phase for Wegovy and Zepbound Is Harder: Lisa Jarvis Bloomberg Law14:50 24-Dec-24

Retail investors buy Novo dip after disappointing weight-loss drug data Yahoo! US14:42 24-Dec-24

Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do? Zacks13:08 24-Dec-24

Novo gets the green light for once-daily haemophilia drug following setbacks Pharmaceutical Technology13:04 24-Dec-24

FDA approves flurry of drugs ahead of holiday season pharmaphorum12:55 24-Dec-24

Nestlé launches protein shots targetting US weight-loss drug users FoodBev Media10:58 24-Dec-24

Domestic firms under duress with new rules Vietnam Investment Review10:15 24-Dec-24

Competition will make weight-loss drugs better, cheaper and bigger Mint08:37 24-Dec-24

Europe’s STOXX 600 inches up as Novo Nordisk surges Business Recorder, Pakistan01:40 24-Dec-24

view more headlines

16 Jan 04:27

About our Novo Nordisk news

Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our NewsNow feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.